<SEC-DOCUMENT>0000950123-11-043118.txt : 20110503
<SEC-HEADER>0000950123-11-043118.hdr.sgml : 20110503
<ACCEPTANCE-DATETIME>20110502175234
ACCESSION NUMBER:		0000950123-11-043118
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110502
FILED AS OF DATE:		20110503
DATE AS OF CHANGE:		20110502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		11802277

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>y91112e6vk.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e6vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>








<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
<DIV align="center"><DIV style="FONT-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>


<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 6-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>REPORT OF PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE<BR>
SECURITIES EXCHANGE ACT OF 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>For the month of May, 2011</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
<B>Commission File Number 000-29962</B></DIV>


<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>Novogen Limited</B>
</DIV>

<DIV align="center" style="font-size: 10pt">
(Translation of registrant&#146;s name into English)</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
<B>140 Wicks Road, North Ryde, NSW, Australia</B><BR>

(Address of principal executive office)</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
<DIV align="center"><DIV style="FONT-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark whether the registrant files or will file annual reports under cover of
Form 20-F or Form 40-F.</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">Form&nbsp;20-F <FONT style="font-family: Wingdings">&#254;</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form&nbsp;40-F <FONT style="font-family: Wingdings">&#111;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation&nbsp;S-T Rule&nbsp;101(b)(l): <FONT style="font-family: Wingdings">&#111;</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Note: Regulation&nbsp;S-T Rule&nbsp;101 (b)( I) only permits the submission in paper of a Form 6-K if
submitted solely to provide an attached annual report to security holders.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation&nbsp;S-T Rule&nbsp;101(b)(7): <FONT style="font-family: Wingdings">&#111;</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Note: Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a Form 6-K if submitted
to furnish a report or other document that the registrant foreign private issuer must furnish and
make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled
or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country
exchange on which the registrant&#146;s securities are traded, as long as the report or other document
is not a press release, is not required to be and has not been distributed to the registrant&#146;s
security holders, and, if discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>









<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><I>Novogen Limited&#146;s Majority-Owned Subsidiary Marshall Edwards, Inc. Enters into Securities
Purchase Agreement</I></U></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On May&nbsp;2, 2011, Marshall Edwards, Inc. (the &#147;<U>Marshall Edwards</U>&#148;), a majority-owned
subsidiary of Novogen Limited (&#147;<U>Novogen</U>&#148;), entered into a Securities Purchase Agreement
(&#147;<U>Securities Purchase Agreement</U>&#148;) with certain accredited investors (the
&#147;<U>Purchasers</U>&#148;) pursuant to which Marshall Edwards has agreed to issue and sell to the
Purchasers: (i)&nbsp;835,217 shares (the &#147;<U>Common Shares</U>&#148;) of Marshall Edwards&#146; common stock, par
value $0.00000002 (the &#147;<U>Common Stock</U>&#148;), at a purchase price of $1.333 per Share, and (ii)
three separate series of warrants. The series A warrants (the &#147;<U>Series&nbsp;A Warrants</U>&#148;) will
initially represent the right to purchase up to 626,413 shares of Common Stock. The series B
warrants (the &#147;<U>Series&nbsp;B Warrants</U>&#148;) will initially represent the right to purchase up to
2,165,534 shares of Common Stock. The series C warrants (the &#147;<U>Series&nbsp;C Warrants</U>&#148;, and
collectively with the Series&nbsp;A Warrants and the Series&nbsp;B Warrants, the &#147;<U>Warrants</U>&#148;) will
initially be exercisable for zero shares of Common Stock, which amount will only be increased (but
not decreased), up to a maximum of 16,000,000 shares of Common Stock, in the event the price of the
Common Stock is below certain levels on certain dates during the one year period ending on the
first anniversary of the date of the closing of the offering.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Upon issuance of the Common Shares, Novogen&#146;s ownership of Marshall Edwards&#146; outstanding Common
Stock will be reduced from approximately 65.1% to approximately 59.0%, subject to further reduction
in the event any of the Warrants are exercised.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In connection with the Securities Purchase Agreement, Novogen and Marshall Edwards have entered
into a voting agreement (&#147;<U>Voting Agreement</U>&#148;), dated May&nbsp;2, 2011. Immediately after the
execution of the Securities Purchase Agreement, pursuant to the terms of the Voting Agreement,
Novogen executed a written consent approving the transactions contemplated by the Securities
Purchase Agreement (collectively, the &#147;<U>Transaction</U>&#148;), which approval will become effective
20&nbsp;days after Marshall Edwards has mailed a definitive information statement to its stockholders
(the &#147;<U>Stockholder Approval</U>&#148;). Consummation of the Transaction is subject to certain
conditions and the closing of the transactions contemplated by the Asset Purchase Agreement, dated
December&nbsp;21, 2010, between Novogen, Marshall Edwards and Novogen Research Pty Limited by May&nbsp;13,
2011.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Also in connection with the Securities Purchase Agreement, Novogen has entered into a lock-up
agreement (the &#147;<U>Lock-up Agreement</U>&#148;) pursuant to which it has agreed not to sell, transfer
or otherwise dispose of any shares of Common Stock or securities convertible or exchangeable for
shares of Common Stock until December&nbsp;24, 2011.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><I>Terms of Warrants</I></U></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Series&nbsp;A Warrants will be exercisable any time on or after the six month anniversary of the
closing of the offering and expire five years thereafter. The Series&nbsp;A Warrants will have an
initial exercise price of $1.57, subject to certain downward adjustments in accordance with the
Series&nbsp;A Warrants. The number of shares of Common Stock issuable upon exercise of the Series&nbsp;A
Warrants will be increased by an amount equal to 75% of the number of shares of Common Stock issued
upon each exercise of the Series&nbsp;B Warrants.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Series&nbsp;B Warrants will be exercisable by the holders at any time on or after the first date on
which certain conditions are satisfied, including that the Stockholder Approval has been obtained
and that all of the Common Shares and shares of Common Stock issuable upon exercise of the Warrants
are able to be resold without restriction or limitation pursuant to an effective registration
statement or Rule&nbsp;144 under the Securities Act. Marshall Edwards may also require the holders to
exercise their Series&nbsp;B Warrants in the event of satisfaction of the conditions set forth in the
first sentence of this paragraph, as well as certain</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">other equity conditions, including certain minimum trading volume requirements. The Series&nbsp;B
Warrants will have an initial exercise price of $1.333 per share, subject to certain downward
adjustments in accordance with the Series&nbsp;B Warrants, and will expire on the first anniversary of
the closing of the offering.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Series&nbsp;C Warrants will be exercisable twenty-six trading days after the earliest to occur of
(1)&nbsp;the date that all securities that Marshall Edwards is required to register in connection with
the Transaction, as well as the shares of Common Stock issuable upon exercise of the Series&nbsp;C
Warrants, can be resold pursuant to an effective registration statement, (2)&nbsp;the date that the
holder can sell all of the shares of Common Stock issuable upon exercise of the Series&nbsp;C Warrants
pursuant to Rule&nbsp;144 without any restrictions or limitations and (3)&nbsp;the six-month anniversary of
the date of the closing of the offering. The Series&nbsp;C Warrants are exercisable solely on a
cashless basis and have a nominal exercise price. The Series&nbsp;C Warrants will expire on the first
anniversary of the date on which the Series&nbsp;C Warrants first become exercisable.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Series&nbsp;A Warrants and the Series&nbsp;B Warrants are subject to certain anti-dilution adjustments,
including upon the sale by Marshall Edwards of any shares of Common Stock or securities convertible
into or exchangeable for shares of Common Stock at a price per share below the exercise price of
the Series&nbsp;A Warrants or the Series&nbsp;B Warrants, or in the event Marshall Edwards subdivides or
combines any of its outstanding shares of Common Stock into a greater or lesser number of shares.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This description does not constitute an offer to sell or the solicitation of an offer to buy any
securities. The Common Shares, the Warrants and the shares of Common Stock issuable upon exercise
of the Warrants have not been registered under the Securities Act or any state securities laws and
may not be offered or sold in the United States absent registration or an applicable exemption from
registration requirements under the Securities Act or applicable state securities laws.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U><B>Exhibit&nbsp;Index</B></U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">Exhibit&nbsp;99.1
</TD>
    <TD valign="top" style="font-size: 10pt">&nbsp;</TD>
    <TD valign="top" style="font-size: 10pt"><DIV style="margin-left:0px; text-indent:-0px">Press release issued May&nbsp;2, 2011 by Novogen Limited.</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link1 " Signature" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Signature</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">NOVOGEN LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">                         /s/ Ronald Lea Erratt
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Ronald Lea Erratt&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Company Secretary&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dated: May&nbsp;2, 2011</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U><B>Exhibit&nbsp;Index</B></U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">Exhibit&nbsp;99.1
</TD>
    <TD valign="top" style="font-size: 10pt">&nbsp;</TD>
    <TD valign="top" style="font-size: 10pt"><DIV style="margin-left:0px; text-indent:-0px">Press release issued May&nbsp;2, 2011 by Novogen Limited.</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>y91112exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px"><B>ASX &#038; MEDIA RELEASE<BR>
2 MAY, 2011</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><IMG src="y91112y9111200.gif" alt="(Novogen logo)"></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>MARSHALL EDWARDS ANNOUNCES PRIVATE PLACEMENT</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Novogen Limited&#146;s subsidiary, Marshall Edwards, Inc., (NASDAQ: MSHL) has made the following
announcement.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">San Diego &#151; 2 May, 2011 &#151; Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company
focused on the clinical development of novel therapeutics targeting cancer metabolism, announced
today that it has entered into a definitive agreement with certain institutional investors to sell
in a private placement common stock and warrants for gross proceeds of up to US$4&nbsp;million, before
deducting fees and expenses of the offering, of which approximately US$1.1&nbsp;million would result
from the sale of approximately 835,217 shares of common stock at US$1.333 per share. The remaining
US$2.9&nbsp;million would be subject to the exercise of one-year series B warrants at their initial
exercise price of US$1.333 per share and the fulfillment or waiver of certain conditions.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company will also issue series A warrants which will initially represent the right to purchase
up to 626,413 shares of common stock exercisable after six months for a period of five years and
subject to proportionate increases to the extent the series B warrants are exercised. Series&nbsp;C
warrants may entitle the holders to obtain additional shares of common stock exercisable in the
event the trading price of the common stock is below certain levels on specified future dates
during a period of up to one year following the closing date.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The offering is expected to close on or about 13 May, 2011, subject to certain customary closing
conditions as well as the closing of the transactions contemplated by the asset purchase agreement
entered into between the Company and its majority shareholder, Novogen Limited, and Novogen
Research Pty Limited on 21 December, 2010, which is pending approval at a meeting of Novogen
shareholders on 6 May, 2011.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The net proceeds from the offering will be used primarily to continue development of Marshall
Edwards&#146; two lead oncology programs, including a Phase I clinical trial of its intravenous drug
candidate NV-143, which has demonstrated pre-clinical activity against a broad range of tumor cell
lines, as well as the necessary studies required to initiate clinical trials of its lead
mitochondrial inhibitor candidate NV-344 later this year.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In conjunction with this transaction, Novogen, Ltd. has entered into a Voting Agreement whereby it
has agreed to vote the common shares in owns in Marshall Edwards, Inc. in favor of the transaction.
In addition, Novogen has executed a Lock-up Agreement stipulating that it will not enter into any
transaction to dispose of the common shares of Marshall Edwards, Inc. that it currently owns until
24 December, 2011.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ROTH Capital Partners acted as the sole placement agent for the offering.</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This press release shall not constitute an offer to sell or the solicitation of an offer to buy any
securities of Marshall Edwards, Inc. nor shall there be any sale of securities in any state or
jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or jurisdiction.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The shares and warrants offered in the private placement and the shares issuable upon the exercise
of the warrants have not been registered under the Securities Act of 1933, as amended, or state
securities laws, and may not be offered or sold in the United States without being registered with
the Securities and Exchange Commission (&#147;SEC&#148;) or through an applicable exemption from SEC
registration requirements. The shares of common stock and warrants were offered only to accredited
investors. The Company has agreed to file a registration statement with the SEC covering the
securities issued in the offering and issuable upon the exercise of the warrants within ten
business days of the closing. Any offering of the Company&#146;s securities under the resale
registration statement referred to above will be made only by means of a prospectus.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Marshall Edwards</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical
development of novel anti-cancer therapeutics. The company&#146;s lead programs focus on two families
of small molecules that result in the inhibition of tumour cell metabolism. The first and most
advanced is a NADH oxidase inhibitor program that includes lead drug candidate NV-143. The second
is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidate NV-344.
Both programs are expected to advance into the clinic in 2011. For more information, please visit
<U>www.marshalledwardsinc.com</U>.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Novogen Limited</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Novogen Limited (ASX: NRT Nasdaq: NVGN) is an Australian biotechnology company based in Sydney,
Australia. Novogen has a consumer healthcare business, conducts research and development on
oncology therapeutics through its subsidiary, Marshall Edwards, Inc., and is developing glucan
technology through its subsidiary, Glycotex, Inc. More information on the Novogen group of
companies can be found at <U>www.novogen.com</U>.</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"># # #
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and
approved by the FDA as being safe and effective for the intended use. Statements included in this
press release that are not historical in nature are &#147;forward-looking statements&#148; within the meaning
of the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform Act of 1995. You should
be aware that our actual results could differ materially from those contained in the
forward-looking statements, which are based on management&#146;s current expectations and are subject to
a number of risks and uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development and/or FDA approval, or
the failure to obtain such approval, of our product candidates; uncertainties or differences in
interpretation in clinical trial results; our inability to maintain or enter into, and the risks
resulting from our dependence upon, collaboration or contractual arrangements necessary for the
development, manufacture, commercialization, marketing, sales and distribution of any products;
competitive factors; our inability to protect our patents or proprietary rights and obtain
necessary rights to third party patents and intellectual property to operate our business; our
inability to operate our business without infringing the patents and proprietary rights of others;
general economic conditions; the failure of any products to gain market acceptance; our inability
to obtain any additional required financing; technological changes; government regulation; changes
in industry practice; and one-time events. We do not intend to update any of these factors or to
publicly announce the results of any revisions to these forward-looking statements.</I></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; FONT-size: 1px">&nbsp;</DIV>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="15%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="55%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>ISSUED FOR</B><BR><BR>
<B>LISTINGS</B><BR><BR>
<B>FOR FURTHER<BR>
INFORMATION</B><BR>&nbsp;<BR>&nbsp;<BR><BR>
<B>ISSUED
BY</B><BR><BR>
<B>CONTACT</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>:</B><BR><BR>
<B>:</B><BR><BR>
<B>:</B><BR>
&nbsp;<BR>
&nbsp;<BR>
&nbsp;<BR><BR>
<B>:</B><BR><BR>
<B>:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>NOVOGEN LIMITED</B><BR><BR>
<B>ASX (CODE NRT), NASDAQ (CODE NVGN).</B><BR><BR>
<B>PETE DE SPAIN, SR DIRECTOR IR AND CORPORATE<BR>
COMMUNICATIONS, MARSHALL EDWARDS, INC.<BR>
TEL &#043;1 858-792-3729<BR>
http://www.marshalledwardsinc.com</B><BR><BR>
<B>WESTBROOK COMMUNICATIONS</B><BR><BR>
<B>IAN WESTBROOK TEL (02)&nbsp;9231 0922</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>y91112y9111200.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y91112y9111200.gif
M1TE&.#EAQP!#`/<```Y860Y96AA;7%)E9J@Y.K,F)[(H*;,I*K0O,+0R,X!L
M;:%R<[IX><.`@=&1DM6:FMBDI-VUM=S/S.#!P.?8U^K>W.WEX_+N[/KU]?__
M_Q+8K```&````!+8A```0````````!+8P!+8K````````0@`X!H`1!YWP"4>
MG!+;2!EKL`)P```#0``#-````````#X`/!+8O`@```$``SH`0U<`7$X`24\`
M1%,`5W,`7',`>64`=#,`;5P`,G,`36T`:68`=&0`+FP`;```````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````!+:Q!@DJ)-TNA+:J!EKL````!4``)0`&BT#,]T`
M&2T#,@```````1EG"````!@S"!+;B)$`70`!-0```!EKL``QZA+:S)#I(!+;
M6)#I()$M@/___Y$M>)%I#@```3P+W9%HU@```````!EKL!8`/)?NR```````
M``@``)?LP)?NR!+@N!+@N#P+W1+;`!+@LAEKL``````!-1+;@)#V7)#V80`!
M-0```!EKL!+;7)%FN!+;Q)#I(``!-0``?A+;D("4,!+@>!+@?````!+;Q)#V
M7)#V80```!+@?!+@>!+;H!EKL!+@2)#I(```````?A+;U("4,```?A+@?!+@
M6(#G<H#FRP!`!5Z"2````"'Y!```````+`````#'`$,`APY860Y96AA;7%)E
M9J@Y.K,F)[(H*;,I*K0O,+0R,X!L;:%R<[IX><.`@=&1DM6:FMBDI-VUM=S/
MS.#!P.?8U^K>W.WEX_+N[/KU]?___Q+8K```&````!+8A```0````````!+8
MP!+8K````````0@`X!H`1!YWP"4>G!+;2!EKL`)P```#0``#-````````#X`
M/!+8O`@```$``SH`0U<`7$X`24\`1%,`5W,`7',`>64`=#,`;5P`,G,`36T`
M:68`=&0`+FP`;```````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````!+:Q!@DJ)-T
MNA+:J!EKL````!4``)0`&BT#,]T`&2T#,@```````1EG"````!@S"!+;B)$`
M70`!-0```!EKL``QZA+:S)#I(!+;6)#I()$M@/___Y$M>)%I#@```3P+W9%H
MU@```````!EKL!8`/)?NR`````````@``)?LP)?NR!+@N!+@N#P+W1+;`!+@
MLAEKL``````!-1+;@)#V7)#V80`!-0```!EKL!+;7)%FN!+;Q)#I(``!-0``
M?A+;D("4,!+@>!+@?````!+;Q)#V7)#V80```!+@?!+@>!+;H!EKL!+@2)#I
M(```````?A+;U("4,```?A+@?!+@6(#G<H#FRP!`!5Z"2`````C^`#,('$BP
MH,&#"!,J''AAH<.'$"-*G$BQHL6+&"U@W,BQH\>/(#=B"$FRI,F3*!-62,FR
MI<N7#R4TA$FSIDV2SR3<W,FS9\1G_'P*'3I4@@"B2)/2K`!`H]*G4$DR'1"U
MJE6,3`&LO,JUZT(+```<]4JVK$`,80&@,LNV:UH`S]K*C2K@[=:Y>(?6?3LS
MK]^=`]Z&_4O8)C_!@PLK;OD,L=C%D$]*</PXLF60E`$HN,R98V:XG4-7#)SY
MKNC3"U%]!H`Z](4*%?H>S)J9:L@*$B2,]&A!YFZS#`@(=_#0@?`(#S$8+\"<
MN0$"Q`^N!J#3H7$"$!!68(#`0/,"!AC^9*\8@8$![\X-(!"O4+C[]_#'$PP^
M_"%]^0@)@/?N5"$#YO@AU$!ZS9WGG0'1$41:9F,MA%Y_#.FW7X'H(8!<1!`@
ML)^!&SH7X$#IH2<B>@T8I-]Y!<B6'W,)YL<A`0[]5\"'!%EP('H,Y"@ABC`2
MU-AJ02DT`7@]$@0!@>'I2"`#R9TH(@%*.E=`D05-^-V5K3!9$`$O.L1E`2T>
MQ"6'-,X'8$(23(C`APYPB`!!%TS'FG]G&CDA`1,4=,%_/"Z$P8$%(.#`;P-5
MX``"K51GT'X4C8GBA0E]&::)YSFZD(QE_HFBE@=A<.*4!.WU69`(@5<`H4.B
M.&FA'')Z$(?^)2Y49@:,3C2FI>UYMRI!7T+PI:L&8;JB=\"*:6J"/ZZ64`3,
M44DKBK.>-6&>QGH7[4.U2O3E!+_F"N9"O:9:@*+!UEG0D=XYFQ"'?<FY#$(R
M0IH!G]\Z5,%^;QJ$;KT891O1MN*:MJ6NX!)\8KX'"6M0=^=%)"ZGJJUFFT$H
M$H3!?NHFY("I'S*<,47^0O0E<B=^G(&D!7][`<?PFCM0F@3_:R!#<A[$;`&N
M;NP=M1!A7)"X//?;L*W>(7>QM2[RFW1T.A?0\HP&-4VH0^)"JL!TI`ZT+:^5
M3B2UF>IY%/)#(PO4]-(I)]@=S@F[+-"M%*E*T'03GS4S07)+=&_^T7C'S-'8
M7O(MT-K%GNPWV@(!72[4!>6M;=<#'::LG6R_;&K0$*V=X,J"_SWTXP5`JOC`
M2HMY.)\(#Z3P0$<S+M&`88>Z&KE?DBMN16O'FH&X*EZT7X[`!U]FV:J#E_K;
MAYM>^K$%K2Z0!9=3I//Q<8[*NO$_FUI1MXEK+S:*5S:W*_'2)H^RMV'N*YOS
M&4"_L_1C)^M8@T>6?GNCQ`XD[M2^&^@_A^/KG$#4Q[724<J`<"N>Z\JW0(C`
M[G@"N1IE&O0E".W.>T0K@.Y@-BZ([(D!N]K/!3!`PA*6,&GR0MYS"K@KK24O
M`WMS'?LRX#B95<X@"T*,1CBG+@YB[B'^CFO=M09B@58$JE2?LV$*86@J2)TO
M4B^<5[9FF$")U+`@HA+,2C9F0!I&42$QE!?#"G<0]T%0((!+V1*E^+DG(HYB
M^9-B`S/PM8@PZWT)R6):XO(E_AENA1*IHT#H!1$S(M$`^`L=$C6(O"ZR$"'H
M:H5&9LC!%IK..PYQS&:,^+&F_5`A/B-()1]BR(.DT5MKS,"^-.)&Y;40;C/,
M`,,,X,>#/.PAB!D`%U/Y+$`6AV4#\T[O#%+*12519`(,)HQ:><`6NB]T`YJC
M*DU%1C@*$R*"$<"8Z/3%@KCOF-T[SQF]B3U3@C-PBM0.Q\SC2!>VDXU00EJU
M&`DN4^G.(=7^2TL<$S(MAW`HE?0RV?/*:4Q$9I"7\&2G)0WW3B^2"2&:VJ=!
M/&4J@1YD,OHLP"<),H%67)$@%6B50C1D(%YR;IRGA&(Z$S++;C9RH7>$%IK4
MM,0VH6B<J4D+<W[)(W)E8$]W<@A)TT4C=*'T/+54*4(S$%.7,G2A)YM0M$(Z
MH?`TH`%?ZI-%=%K-<R&)`0T(SI)$UB'U`&]MXCSD_]8*0?)%:D(+E1!4.2=/
M.EFIK%!5"$9;(3"%7&!'Z+&2A222H0VAR'_-*E7X%FM07C%GJ3^%ZZ6",T0Z
M`G,A%UC.=YY368?4Q:*S$>MF&0!9A$R`.^%#``$:T%?5!>^UKS5.2%CQQ-.&
M4F0D247(!20P@0E4(+<3D8`"2HL0"_36MQZIP'$E8,&>X+8UT(VN=*=+W>I:
=][K8S:YVM\O=[GKWN^`-KWC'2][RFO>\;`D(`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
